SCHEDULE: Sio Capital Management Discloses 5.77% Stake in PMV Pharmaceuticals

Sio Capital Management, LLC has reported a beneficial ownership of 5.77% in PMV Pharmaceuticals, Inc. as of March 31, 2026.

Summary

• Sio Capital Management, LLC (Sio) has filed a Schedule 13G, indicating it beneficially owns 3,076,580 shares of PMV Pharmaceuticals, Inc. common stock.
• This ownership represents 5.77% of the class of securities outstanding as of March 6, 2026.
• Sio acts as an investment adviser to affiliated funds that hold these shares.
• The filing specifies shared voting power and shared dispositive power for these shares.
• Michael Castor, who controls both Sio and Sio GP, LLC, may be deemed to beneficially own these shares.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this filing as neutral, as it reports an ownership stake without providing operational or financial performance details that would indicate a strong positive or negative sentiment.

Positives

• Sio Capital Management has taken a significant stake, showing confidence in PMV Pharmaceuticals.
• The 5.77% ownership indicates a notable investment by an institutional entity.

Negatives

• The filing does not contain any negative financial results or operational issues.
• No specific negative forward-looking statements are present.

Risks

• The filing does not explicitly detail specific risks related to PMV Pharmaceuticals' business operations.
• Potential risks associated with investment concentration for Sio Capital Management are not detailed.

Future Outlook

The filing is a Schedule 13G, which reports beneficial ownership and does not contain forward-looking statements or guidance regarding the company's future performance.

Management Comments

• Sio Capital Management, LLC acts as an investment adviser to certain affiliated funds that directly hold the shares of Common Stock to which this statement relates for the benefit of their respective investors, and in such capacity Sio has voting and dispositive power over such shares.
• Michael Castor may be deemed to control the voting and dispositive decisions with respect to, and therefore be the beneficial owner of, the shares of Common Stock reported on this Schedule 13G.
• Neither the filing of this Schedule 13G nor any of its contents shall be deemed to constitute an admission by the GP or Michael Castor that such person is the beneficial owner of any of the equity securities referred to herein for purposes of Section 13(d) of the Exchange Act, or for any other purpose, and such beneficial ownership is expressly disclaimed.

Industry Context

StockSavvy.ai notes that Schedule 13G filings are common for institutional investors accumulating significant stakes in publicly traded companies, indicating a belief in the company's value or potential. This filing by Sio Capital Management suggests an active investment strategy in the biotechnology or pharmaceutical sector where PMV Pharmaceuticals operates.

Stakeholder Impact

• Shareholders: The increased institutional ownership may signal investor confidence, potentially influencing share price, but the filing itself does not provide direct operational news.
• Management: The filing confirms an institutional investor's significant stake, which may lead to increased engagement or scrutiny from Sio Capital Management.
• Creditors: No direct impact is indicated by this ownership filing.

Next Steps

• Sio Capital Management will continue to manage the investment in PMV Pharmaceuticals on behalf of its clients.
• Further filings may be required if Sio's ownership stake changes significantly.

Key Dates

Keywords

PMV Pharmaceuticals, Schedule 13G, Sio Capital Management, Beneficial Ownership, Investment Adviser, Common Stock, SEC Filing